Meeting Coverage > > ASH: Hematology– Better 2-year PFS, OS, however not appropriate to main refractory illness
by Charles Bankhead, Senior Editor, MedPage Today December 10, 2023
SAN DIEGO– Autologous stem-cell transplant (ASCT) resulted in enhanced results as compared to CAR T-cell treatment for clients with fallen back big B-cell lymphoma (LBCL) in total remission, a retrospective analysis revealed.
Clients who went through ASCT had less regressions at 2 years (27.8% vs 48.0%) and much better progression-free survival (PFS, 66.2% vs 47.8%), and general survival (OS, 78.9% vs 65.6%). In the subgroup of clients with early treatment failure, ASCT was connected with a lower 2-year regression rate (22.8% vs 45.9%). Treatment-related death did not vary in between the 2 kinds of treatment.
By multivariate analysis, CAR T-cell treatment was related to a greater danger of regression and inferior PFS, reported Mazyar Shadman, MD, of the University of Washington and Fred Hutchinson Cancer Center in Seattle, at the American Society of Hematology (ASH) conference.
“The message here is that this information might be practice notifying and validating,” Shadman stated throughout an ASH press instruction. “In clients who regression after first-line treatment after 12 months, the present requirement of care is salvage treatment with autotransplant.
